Anesiva files for bankruptcy after Arcion merger falls through

The updated US FDA label modifies dose titration based on TRAILBLAZER-ALZ 6, a study that showed a more gradual rise in dosing levels reduced ARIA-E incidence without reducing amyloid clearance.

The company is expecting US FDA approval of the drug in a bigger indication, major depressive disorder, later this year.

Still holding out hope after multiple rejections for the tyrosine kinase inhibitor.

Psychedelics appear to be in vogue after years of being relegated to alternative medicine. But investor pushback after the highly anticipated release of Phase III trial data by Compass Pathways reveals an increasingly high bar for development.